Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma

Conditions

• Cutaneous Angiosarcoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Ivonescimab — DRUG
  Given by IV

Study Details

This is a pilot study evaluating the efficacy and safety of ivonescimab in subjects with advanced or metastatic cutaneous angiosarcoma who have previously been treated with taxane-based chemotherapy.

Key Dates

First listed

Jun 18, 2026

Start date

Aug 19, 2026

Status verified

Aug 2026

Primary completion

May 11, 2027

Completion

May 11, 2029

Study Design

Enrollment

10 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment with Ivonescimab
  Participants will be treated with ivonescimab (20 mg/kg IV on Day 1 Q3W). The treatment will be repeated every 3 weeks until progressive disease (PD), intolerable toxicity, initiation of new anti-tumor therapy, withdrawal of informed consent, lost to follow-up, completion of therapy, death, or any other investigator-determined reasons for treatment discontinuation (whichever occurs first).

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

• Michael Nakazawa, MD
  713-785-7017
  [email protected]

Locations (1)

Find similar trials in Houston, TX